GlaxoSmithKline Plc announced its Covid-19 antibody treatment is effective against the mutations in the new Omicron variant, according to a report by Bloomberg on Tuesday.
- The drugmaker stated that a test performed in-vitro against a pseudo-virus showed that Glaxo’s antibody treatment deals with all mutations in the spike protein of the Omicron variant.
- Shares of Vir Biotechnology Inc., the partner in developing the drug, jumped nearly 7.4% in pre-market trading.
- Glaxo shares rose 0.5% in London after the results that the drugmaker’s vaccine developed in partnership with Medicago Inc revealed efficacy against a number of COVID-19 variants.
- Glaxo’s observations come amid concerns of uncertainty on if Omicron deteriorates the defenses of the current medicines and vaccines.
Glaxo had stated last week that the drug was effective against any mutations in Omicron, but the recent tests confirm that it could hold against the worrying variant. GSK up +0.70%, VIR up +6.12%, Pre-market trading